Continuing Education Information: Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
© 2022 Harborside™
ARTICLE
Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life
| Read the Certified Article |
This CPE/CNE/AAPA-certified supplement is provided by
|
Release date: 5/25/2022 |
Estimated time of completion: 30 minutes |
|
Expiration date: 5/24/2023 |
Media: Certified journal article |
TARGET AUDIENCE
This educational activity is designed for advanced practitioners (nurse practitioners, pharmacists, physician assistants), as well as hematologists, surgeons, pathologists, orthopedic specialists, primary care, emergency medicine, and other health-care professionals who are part of the interprofessional team responsible for the therapeutic management of patients with hemophilia A.
ACTIVITY OVERVIEW
Hemophilia A is an X-linked genetic disorder characterized by a deficiency in normal factor VIII, resulting in an increased risk of bleeding. Repeated bleeds, notably in the joints, lead to chronic pain and loss of function. Joint damage can be prevented, at least in part, with prophylactic factor VIII replacement. Although factor VIII can be replaced, its intravenous administration is burdensome, which may impair adherence. Furthermore, inhibitors (neutralizing alloantibodies to factor VIII) will develop in approximately 30% of patients treated with factor VIII—making factor VIII replacement ineffective. Although patients with inhibitors can be treated with bypassing agents, these agents are expensive and less predictable than factor VIII.
However, there is now another option for patients with and without inhibitors: bispecific antibody nonfactor replacement prophylaxis. It is important for the interprofessional care team to be aware of how this treatment compares with traditional prophylactic agents, its safety and efficacy data, and how to appropriately incorporate prophylaxis therapy based on the latest real-world clinical data.
This educational activity will review currently approved prophylaxis therapy in hemophilia A, the benefits of prophylaxis and adherence, and patient quality-of-life factors. Interprofessional perspectives from an expert faculty panel will be featured.
LEARNING OBJECTIVES
At the conclusion of this activity, participants should be better able to:
- Evaluate currently available prophylactic therapies for hemophilia A to select the treatment best suited to the individual patient
- Analyze currently available safety and efficacy data from clinical trials and real-world studies on bispecific antibody nonfactor replacement therapy to make informed management decisions
- Incorporate quality-of-life and cost data into shared decision-making with patients to maximize treatment adherence
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
AUTHORS
Miguel A. Escobar, MD, Professor of Medicine and Pediatrics, University of Texas Health Science Center
Director, Gulf States Hemophilia & Thrombophilia Center, Houston
Cindy Leissinger, MD, Professor of Medicine, Tulane University School of Medicine
Director, Louisiana Center for Bleeding and Clotting Disorders, New Orleans
Guy Young, MD, Director, Hemostasis & Thrombosis Center, Children’s Hospital Los Angeles
Professor of Pediatrics, University of Southern California, Keck School of Medicine
ACCREDITED CONTINUING EDUCATION
Accreditation Statement
In support of improving patient care, AXIS Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.
Credit Designation for Physician Assistants
AXIS Medical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 5/24/2023. PAs should only claim credit commensurate with the extent of their participation.
Credit Designation for Pharmacists
This knowledge-based activity is approved for 0.5 contact hours of continuing pharmacy education JA4008106-0000-22-001-H01-P.
Credit Designation for Nursing
AXIS Medical Education designates this continuing nursing education activity for 0.5 contact hours.
Learners are advised that accredited status does not imply endorsement by the provider or ANCC of any commercial products displayed in conjunction with an activity.
AXIS Contact Information
For information about the certification of this activity, please contact AXIS at info@axismeded.com
Fee Information
There is no fee for this educational activity.
Method of Participation and Request for Credit
To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures and actively participate in the educational activity. At the conclusion of your article participation, please visit https://ok.cx/HEMA Enter Access Code: 2505-HEMA
Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be immediately available to you.
Disclosure of Conflict of Interest
AXIS Medical Education requires faculty, instructors, authors, planners, directors, managers, reviewers, and other individuals who are in a position to control the content of this activity to disclose all real or apparent conflicts of interest they may have with ineligible companies. An ineligible entity is any organization whose primary business is producing, marketing, selling, re-selling, or distributing health-care products used by or on patients. All relevant conflicts of interest are identified and mitigated prior to initiation of the planning phase for an activity.
AXIS has mitigated and disclosed to learners all relevant conflicts of interest disclosed by staff, planners, faculty/authors, peer reviewers, or others in control of content for this activity. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation or activity. Disclosure information for faculty, authors, course directors, planners, peer reviewers, and/or relevant staff is provided with this activity.
The faculty reported the following relevant financial relationships or relationships they have with ineligible companies of any amount during the past 24 months: Miguel A. Escobar, MD, reported a financial interest/relationship or affiliation in the form of Consultant: Biomarin; Kedrion Biopharma; Rani Therapeutics; Magellan Pharmaceuticals; Takeda Pharmaceutical Co, LTD; sanofi; uniQure; CSL Bering; Genentech, Inc; Novo Nordisk; and Pfizer, Inc. Serve(d) as a speaker or a member of a speakers bureau for: CSL Bering; Novo Nordisk; Pfizer, Inc; Kedrion Biopharma; Roche; and Bayer HealthCare, Inc. Contracted research: Takeda Pharmaceutical Co, LTD; Novo Nordisk; uniQure; sanofi; Pfizer, Inc; Opto Biologics; and Genentech, Inc. Cindy Leissinger, MD, reported a financial interest/relationship or affiliation in the form of Advisory board: Bayer HealthCare, Inc; CSL Bering; Catalyst Pharmaceuticals; Genentech, Inc; uniQure; sanofi; and Takeda Oncology. Contracted research: BioMarin Pharmaceutical, Inc. Guy Young, MD, reported a financial interest/relationship or affiliation in the form of Serve(d) as a speaker or a member of a speakers bureau for: Genentech, Inc; BioMarin Pharmaceutical, Inc; sanofi; Takeda Oncology; and Grifols. Consultant: BioMarin Pharmaceutical, Inc; Genentech, Inc; Spark Therapeutics; sanofi; Novo Nordisk; and Takeda Oncology.
The directors, planners, managers, and reviewers reported the following financial relationships they have with any ineligible company of any amount during the past 24 months: Linda Gracie-King, MS; Jocelyn Timko, BS; Marilyn L. Haas-Haseman, PhD, RN, CNS, ANP-BC; and Adrienne N. Nedved, MPA, PharmD, BCOP, hereby state that they do not have any financial relationships or relationships any ineligible company of any amount during the past 24 months. Robert Mocharnuk, MD, reported a financial interest/relationship or affiliation in the form of Common stock: Merck of any amount during the past 24 months.
Disclosure of Unlabeled Use
This educational activity may contain discussion of agents that are not approved for use by the FDA and/or investigational (“off-label”) uses of agents that are approved by the FDA. The planners of this activity do not recommend the use of any agent outside of its labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each agent for information on its approved indications, contraindications, warnings, and other, related information.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
| Read the Certified Article |
How to Earn Credit
Click the button below to access the learning assessment and evaluation form online. Enter Access Code: 2505-HEMA.
| Earn Credit |
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 75% on the learning assessment) and complete and submit the evaluation form will be able to immediately download a statement of credit.
Pharmacists: Upon entry of your NABP e-profile number (usually 6–7 digits) and your date of birth in MMDD format, your record will automatically upload to CPE Monitor.